Correlation of Dosimetric and Clinical Factors With the Development of Esophagitis and Radiation Pneumonitis in Patients With Limited-Stage Small-Cell Lung Carcinoma
- 1 December 2014
- journal article
- Published by Elsevier BV in Clinical Lung Cancer
- Vol. 16 (3), 216-220
- https://doi.org/10.1016/j.cllc.2014.11.008
Abstract
No abstract availableKeywords
This publication has 15 references indexed in Scilit:
- Predicting Esophagitis After Chemoradiation Therapy for Non-Small Cell Lung Cancer: An Individual Patient Data Meta-AnalysisInternational Journal of Radiation Oncology*Biology*Physics, 2013
- Effect of Normal Lung Definition on Lung Dosimetry and Lung Toxicity Prediction in Radiation Therapy Treatment PlanningInternational Journal of Radiation Oncology*Biology*Physics, 2013
- A literature-based meta-analysis of clinical risk factors for development of radiation induced pneumonitisActa Oncologica, 2012
- Systematic review of dose–volume parameters in the prediction of esophagitis in thoracic radiotherapyRadiotherapy and Oncology, 2009
- Phase II trial of irinotecan and cisplatin with early concurrent radiotherapy in limited-disease small-cell lung cancerCancer, 2007
- Concurrent Chemoradiotherapy for Limited-disease Small Cell Lung Cancer in Elderly Patients Aged 75 Years or OlderJapanese Journal of Clinical Oncology, 2007
- Radiation pneumonitis following concurrent accelerated hyperfractionated radiotherapy and chemotherapy for limited-stage small-cell lung cancer: Dose–volume histogram analysis and comparison with conventional chemoradiationInternational Journal of Radiation Oncology*Biology*Physics, 2006
- Concurrent chemotherapy (carboplatin, paclitaxel, etoposide) and involved-field radiotherapy in limited stage small cell lung cancer: a Dutch multicenter phase II studyBritish Journal of Cancer, 2006
- Twice-Daily Compared with Once-Daily Thoracic Radiotherapy in Limited Small-Cell Lung Cancer Treated Concurrently with Cisplatin and EtoposideThe New England Journal of Medicine, 1999
- Importance of timing for thoracic irradiation in the combined modality treatment of limited-stage small-cell lung cancer. The National Cancer Institute of Canada Clinical Trials Group.Journal of Clinical Oncology, 1993